a thank for and call for us ir.navidea.com, joining being made Thank earnings you call today and website, our the live This will and here be webcast available. you, on all replay business is update.
remarks, conducting a we you've session, live be heard. will prepared Q&A as Following just
and of Vice of Directors, Eves; Mr. of its Mr. controller, President Navidea's Ms. Board Finance its of Chair Administration, Alex Cappello; Meyer, joining Scott; its Joe its Directors, Board the of and call Vice are Chair on me Mr. Kim today. Erika all the
During develop the and data matters. making the conference resources molecular which immunotherapeutics, Navidea's our These and we events forward-looking of capital and performance strategic will to the company. diagnostics developments clinical and course be of of clinical and this timing future events readouts, include future to statements regulatory with plans regarding along relate call, business
SEC. information, expectations based carefully uncertainties All described most of recent as and are new and or to a differ of of actual included These these could risks forward-looking should of company's materially. the statements well and factors beliefs and in cause safe on update no our whether within results statements, of involve as harbor quarterly events filings assumptions, as revise read result Investors website obligation assume the otherwise. the future today. the as with uncertainties risks section to management statements certain We the and or the annual risk
reiterate we and RA, our it our of to providers Board QX look would events XXXX our key discussions in thought full areas to Two, rheumatoid and identify support submission of RA trial III I actively approval. our planning. trial fully Directors Phase a begin the and of trial, mission update from of we in at NDA Phase in with FDA continue One, few As be arthritis, we'll capital the will III funding. helpful fund full is to focus date, enrollment, success to engaged back this
funded Our industry's goal attract top be Three, is we'll to and this retain year. biopharmaceutical fully talent. the
development As our and so our does and success. key trial help initiate strategic milestone support grow achievements, to team need success milestone the to our key and RA way support efforts a IR new grows, share to program identify relationships as PR
actively shortly. quarter, As I moment mentioned on to engaged trials our we Board last our the a effort, we diagnostic other arthritis have financing In advanced front, is the in of have our indications in rheumatoid there pipeline financing therapeutics. announce to ago, well the hope clinical and and Directors in news as as in
expression These in XX on Phase at nonfibroid QX, And continue promising the pathotype international in in tilmanocept our IIb presented excellent our make updated imaging to distinguish fibroid CDXXX joints biomarker We conference a support from to evaluated presentation. hypotheses we solid first rheumatoid as our of the provide patients imaging the and time during tilmanocept's RA. trial biopsy. early the strong results of data results of comparing preliminary supporting the arthritis of progress with by support to in an ability participants
enrolling in continue are into also Phase enroll and RA We to III sites. the actively XX
the We intellectual the well-known globe with imaging continue grow and company's we existing and institutions to advance collaborations to our key through property. work applications therapeutics as across investigators
here and our of and benefit shareholders our proud are the at planning place made are the have We in associates Navidea. progress putting we to we
both. Dr. essentially Regarding litigation exposure the CRG that and matters, the bracket its company that Goldberg has ruling in
exposure. minimize to continue will We
results. brief update our to Now specific clinical I'd like a to provide
are: The into this or initial to in III, patients to of indications and RA I'll have in So low first-time new two, to therapy. RA. localization alpha level we therapy; continue to prediction In approval pursuing anti-TNF good III with one, alpha a identify progress likely rheumatoid the response NAVX-XX, are are with Phase our respond we less begin for enrollment anti-TNF FDA the early of trial program. treatment of arthritis tilmanocept, Phase who
As for of long-term we disease patient's bring the Because have a them discussed that patient reliable is large is therapy previously, also unmet lead is need can a working consequences, with for treated, high there effects. to is drug being not the with RA. health early a side and a predictor if with this possible costs working, whether ineffective unnecessary along not therapies in drug
Phase the treatment of that tilmanocept patients serve as addressing anti-TNF switching therapy, unmet alpha medical ability trial an Our of will an response in RA predictor to need. imaging III establish early to
study In recruitment. comparison our remain tilmanocept to active imaging NAVX-XX, we in joint of biopsy,
As have previously, promising. we've announced preliminary and the discussed of this results trial been
trial lympho-myeloid. patients of in X obtain Our results. the of each RA aim is the minimum of and comparative X RA: is enroll a that with so diffuse X subtypes pathology designed fibroid, recruit to we And pathotypes the imaging and subjects myeloid each of to of
expected both completed. overall we enrollment X out in our and X joint range So buckets, those targets pathotype those of of been XX patients having their achieved has to between have biopsies size trial imaging with -- had date, XX. and To
not pathobiology likely study between less pathotype an and individual is of to the Knowledge this a a RA responsive of a body of has anti-TNF patients of which the important therapy determining joint-specific patient's RA-involved of is patient means important whether key growing objective may assess fibroid particular may respond. rheumatology. is of relationship leaders is this drugs, a There it joints. to those tilmanocept to as seen opinion alpha because the are so clinically type or RA be patient predict uptake and the to RA values a that extremely primary literature The suggesting pathotype number in to of with much the
that biopsy, of pathotype by other tilmanocept assessing provide a As patient's of could reliable than this information. hypothesized no is RA a doing this time, have we there of way and
able we rheumatology world. the on results uptake updated first These back That's there the of at patients with is macrophage results the presented is the November's diffuse preliminary differentiate to tilmanocept in or types College patients joints RA, either XX that involvement. pathotype, fibroid macrophage patients conference in American that So myeloid indicated having of the low patients from RA-inflamed that higher lympho-myeloid with discretely those involvement, Rheumatology with meeting. presented is largest the
if III support one trial. is provides type a of fibroid baseline alpha they our scan has meaningful clinical alpha that increasing also data anti-TNF receive for therapy. these likely the a as ability are a Since, is an patient receive predict benefit whether indications The mentioned, from I from benefit the to to in So Phase likely clinical to RA, alone, anti-TNF less a therapy. from of there patient evidence significant
You uptake on pilot low might assessment. in started nonresponse their treatment a recall they almost prediction imaging joints a before baseline therapy arm tilmanocept standard in of alpha those that a XX% an tilmanocept scan that level response, of contained clinical at rate completed the had our at their exhibited therapy anti-TNF gold of using patients to efficacy previously IIb study, looking Phase NAVX-XX, early who
the better pharmaceutical prior companies discussions these these companies even results data have be And being now and with as will imaging up is more conversations key The move kind completion, these with biomarker position hand. with with have and we data which in differentiator this used as possibility in development work. hold, of we their forward an pipelines. in trial are discussions companies between who that of for additional results early RA, if gather to we we towards promising a Importantly, promising current opened tilmanocept with had drug therapeutics developing have for
well, will commercial very imaging product. have significant quantification good automating as We to which the benefit on continue make the progress for
image be We definitive for partner M-I-M, closely quantification imaging working commercial with RA. in are on Software, MIM of tilmanocept to agreement our them for a
again, a MIM with medical leading space. imaging is software in a once in nuclear Cleveland company footprint based medicine the large So
their this are well image normative trial trial, workflow should existing data. analysis trial our be as their Phase used as into image currently III our the integrating for analysis We for and database software
them development The for workflow should workflow this Already, be a automated developing. fully this is well into by trials these of trials are designed. integrating And integration helpful they our stage, and that using for at that should they application from fully our a our be robustly trials, data have earlier algorithm. pilot study quantitative proprietary demonstrating automated able using reproduce develop this our completed to reads can that they extremely imaging
large-scale to imaging including important large barrier methodology competitors a of heard room of automated mind this, space. well serves to images, for normative is reads data also rapidly which but ability as entry perform possible as product. and a is is accurate analysis in of the of all scale the tilmanocept a of to built, without before, be interest will in go it to method, the and will this most quantitative database upon driving us bunch sensitive the critical help discuss for not the only that RA. reproducibly Keep have of read that objective the and our you've in RA regions us reference actually image the having it The This to as drawing critical people to at through commercial rollout adoption this significant
with using over earlier conversion to might of patent application patent outcome treatment also You application a in alone. using This imaging combination to for seen clinical the our our improve our imaging serological possibly readout predictive involves provisional markers application and AX have an month. this capacity
on if will we if approaches combinatorial work they So granted. have IP as well and protection
referenced from indeed suggests data the We a that might while have Phase completed IIb that just that trial was I NAVX-XX ago work. this
on new in pipeline researchers atherosclerosis. PET preclinical similar related with Birmingham tilmanocept mouse agents. preclinical a at on studies or We've University agents our UAB. next-generation work evaluating in for and diagnostics We we've of work on NIH-funded the completed various imaging model in of development, Manocept studies the imaging this tilmanocept gallium-XX completed also In Alabama tilmanocept at for imaging collaboration gallium-XX to
our as constructs competitive work UAB. intravenous explored injection of the blocking. was molecular Work the and it organs important localization following constructs of significantly collaborators Results increase by to tissues This such of showed that compounds tumors and their tilmanocept-like introducing reducing evaluating on weights these with while and agents, and molecular therapeutic varying off-target weights the varying tilmanocept-like preclinical to competitive biodistributions, possible liver. another at studies without was with set localization imaging completed of blocking like concurrently target to
Molecular improving targeted constructs results a macrophage valve We the effective in can Journal of year These to pathology. the our path electronically Molecular of on other published that and to and this presented these diagnostic and greater and therapeutic of results imaging delivery sites and our tumors of more show to online. and access at meeting X and these Medicine were summer, Imaging Nuclear you last Society Imaging and Biology, March
also constructs On immune new another therapeutic the growth altering combination XXXX. payloads advance drug effective spaces on and tumor the human of administered company. more These that these has with the candidates inflection example. assets beneficially in for the and investigational front, progressed. may are for opportunities new targeted of and than in be applications we oncology an goal advancing when carry drug drug, or These to by Work deals in average studies reduce and have trials of rate drug demonstrated macrophages, to cancer status in mouse tumor with payloads our therapeutic partnering models the that licensing of constructs preclinical new Results delivery anti-inflammatory significantly will doxorubicin points the alone XX%. new for for new filings be significant in constructs filing
held our results the Summit Annual of Therapy XX, were Myeloid-Directed More full the the of results novel recently, meeting. presented November were the of at bisphosphonate Some Boston. Meeting for of at for Cancer Immunotherapy covering constructs payload bisphosphonate the and presented paclitaxel Tumor Society spectrum new on constructs in
what's completed a of design in future. bisphosphonate-carrying this called study the of evaluate study efficacy construct we of tolerated results this will maximum mice construct. dose studies for addition, In to in facilitate anticancer our The intended
a choose All to work are immunotherapy phenotype-altering intended cancer with potential macro-type-, enable preclinical candidate indications. Navidea drugs for of for oncology lead to our constructs
to in are are sell priority chronic United common subtropics States, the sandflies candidates. protozoan is called humans Leishmaniasis potentially The also back of a parasite of in disease that other the more of ongoing of leishmaniasis. in leishmaniasis countries therapeutics it FDA is well bite vector-borne Navidea where serious U.S. Preclinical Southern pipeline enough vectors a the development It's in and caused Europe. the the transmitted tropical disease, accelerate number a for to in replicates CDXXX-positive through as parts what's but for a rare infected by has studies as found as designated sandfly that and tropics, tropical disease disease. potentially eligible is could review macrophages. a potentially a found, voucher making neglected of life-threatening than new this more cost It cover
Previously, of by Navidea created numbers implications by that of observed control construct. the to significant immune in novel leishmaniasis CDXXX the therapeutic of a in expressing leishmanial mechanism the with Concurrent that were alterations status from our separate mice. experiments has reduced of the action collaborators macrophages NIH results dominant form at the Navidea of published in in the scientists these potential X has parasites, high are showing last a infections our therapeutic This demonstrating and the disease. lesions results role significantly with that research advanced year play novel construct with project for caused potential
ongoing results. to these are experiments our follow promising or plan up on Additional initial very
to of overall property the received States for This response from nature I studies, Trademark That of of Macrophage intellectual to For including change preclinical ability payloads company's Altering Efficacy covers against And spoke macrophages patent to front. of of make demonstrated targeted these We issuance the titled been in an immune a our our Phenotype. me Compositions Methods more delivery stimulate Patent through of the brings constructs just them has Office patent ones the the and United notification application constructs about. tumors that pro-inflammatory.
of the issuance call and Canada. for of press We from application patents earnings also in to release received more have notifications today detail. refer Israel Please earlier in of patent
applications So to we new on provisional ones. submit work our and continue pending
constructs, new We next-generation mannosylated provisional a a holding currently This partnership linkage provide excellent active needed will of linkage new our next-generation the used, our filed agents our therapeutic an describing designed mannose stable commercial both of to the for imaging dextran-based is and and and our therapeutic have we more is patent In to chemistry a to well addition patent that scale-up therapeutic disease results application constructs. the onto for mannose chemistry imaging different and new sugars one constructs. than current and have in indications. molecules strategy that protection and production attorneys, as with protections our our IP and as to rights diagnostic company facilitate
and the the strategy and The for world, Lymphoseek we has find and distribution regarding focusing the the Lymphoseek in On to Europe beyond. strategy the this other and of partnering Lymphoseek rest candidates distribution. Europe front, partners of marketing for company been our marketing on remains is and long-term pipeline right for reason for are and
a On we in readiness our been stream and front the of continues. for continue and product pharmaceutical able supply. this Lymphoseek product reliable Lymphoseek to with Lymphoaim supplier both RA well supplier. to active of these to countries. we API are ingredient as partners supply work a or and and for India for drug commercial and of implications have manufacturing supply completion as China as drug and product, clinical has as final in the And advancing need work new time, steady through be in a This these towards and Progress we
continue biopsy the the these the imaging, trial and the largely highlights the on diagnostic just push update. specifically indications. Phase quarter Phase touch for on are we We pipeline, the focused wanted So to this of while and our to remain last that therapeutic IIb progress some III, RA of on we other in support
to and trial work. I for clinical research their and always, want network here our keep collaborators of tireless to for moving academic their sites team things hard all thank efforts As the of
pipeline our marketing. commercialization appropriate key for business strategy remains and seek to products and partnerships points inflection advance Our to
for close -- So the with summary to to it now over want the to that, you, I'll update. financials. turn update I'm going I thank and Erika
